Table 3 Clinical and treatment data of children with HIV/AIDS ^α Treated in four ART ^¥ Centers in Addis Ababa, Ethiopia followed from 2005-2011

Weight for Age

 -Below 3^rd centile€

52(30.2)

120(69.8)

2.74(1.09-6.89)

0.54(0.13-2.25)

 >3^rd < 97^th centile

107(55.7)

85(44.3)

0.79(0.32-1.92)

0.41(0.11-1.55)

 Above 97^th centile

6(13.6)

38(86.4)

1

1

Height for Age

 Below 3^rd centile

88(27)

239(63)

2.61(1.29-5.29)

3.25(1.00-10.58)

 >3^rd < 97^th centile

66(8.7)

697(91.3)

0.67(0.33-1.37)

1.05(0.33-3.33)

 Above 97^th centile

10(22.2)

71(77.8)

1

1

Weight for Height

 Below 3^rd centile

15(14.3)

90(85.7)

1.10(0.61-1.98)

 >3^rd < 97^th centile

41(16.7)

204(83.3)

1.33(0.89-1.98)

 Above 97^th centile

93(13.2)

614(86.8)

1

WHO Clinical stage

 Stages 1 or 2

58(12.7)

400(87.3)

0.84(0.59-1.18)

 Stage 3 or 4

107(14.8)

617(85.2)

1

Adherence to HAART

 Optimal

162(14)

1006(86)

0.41(0.15-1.19)

 Suboptimal

5(27.3)

13(72.7)

1

Initial HAART Regimen

 PI based ^£

10(32.3)

21(67.7)

3.03(1.40-6.55)

1.05(0.33-3.89)

 NNRTI + NRTI

157(13.6)

998(86.4)

1

1

HAART drug substitution

 Yes

29(23.6)

94(76.4)

2.07(1.31-3.25)

1.695(1.053-2.728)

 None

138(13)

925(87)

1

1

HAART Dosing preparation

 Fixed

9(17.6)

42(82.4)

1.18(0.56-2.49)

 Separate

109(15.4)

600(84.6)

1

CD₄ Count at initiation

(cells/mm3)

 <50

19(23.8)

61(76.2)

2.39(1.38-4.15)

2.30(1.28-4.14)

 ≥50

112(11.5)

859(88.5)

1

1

Chronic Diarrhea after initiation of ART^¥

 Yes

6(37.5)

10 (62.5)

3.76(1.35-1.50)

3.44 (1.37-8.62)

 None

161(13.8)

1009(86.2)

1

1